1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/60528
Full metadata record
DC FieldValueLanguage
dc.creatorDaniela Pagliara Lagept_BR
dc.creatorJoão Augusto Oliveira-da-silvapt_BR
dc.creatorFernanda Fonseca Ramospt_BR
dc.creatorGrasiele de Sousa Vieira Tavarespt_BR
dc.creatorFernanda Ludolf Ribeiropt_BR
dc.creatorRaquel S. Bandeirapt_BR
dc.creatorIsabela A. G. Pereirapt_BR
dc.creatorMiguel Angel Chaves Fumagallipt_BR
dc.creatorBruno Mendes Roattpt_BR
dc.creatorRicardo A. Machado-de-ávilapt_BR
dc.creatorMyron Christodoulidespt_BR
dc.creatorDanniele Luciana Valept_BR
dc.creatorEduardo Antonio Ferraz Coelhopt_BR
dc.creatorVívian Tamietti Martinspt_BR
dc.creatorFlávia P. Linharespt_BR
dc.creatorCamila Simões de Freitaspt_BR
dc.creatorAmanda Sanchez Machadopt_BR
dc.creatorJamile M. O. Cardosopt_BR
dc.creatorDaysiane de Oliveirapt_BR
dc.creatorNathalia Coral Galvanipt_BR
dc.creatorMarcelo P. de Oliveirapt_BR
dc.date.accessioned2023-11-06T20:47:34Z-
dc.date.available2023-11-06T20:47:34Z-
dc.date.issued2022-
dc.citation.volume10pt_BR
dc.citation.issue7pt_BR
dc.citation.spage1146pt_BR
dc.citation.epage22pt_BR
dc.identifier.doihttps://doi.org/10.3390/vaccines10071146pt_BR
dc.identifier.issn2076-393Xpt_BR
dc.identifier.urihttp://hdl.handle.net/1843/60528-
dc.description.resumoCurrently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, a recombinant chimeric protein ChimT was developed based on T-cell epitopes identified from the immunogenic Leishmania amastigote proteins LiHyp1, LiHyV, LiHyC and LiHyG. ChimT was associated with the adjuvants saponin (Sap) or monophosphoryl lipid A (MPLA) and used to immunize mice, and their immunogenicity and protective efficacy were evaluated. Both ChimT/Sap and ChimT/MPLA induced the development of a specific Th1-type immune response, with significantly high levels of IFN-γ, IL-2, IL-12, TNF-α and GM-CSF cytokines produced by CD4+ and CD8+ T cell subtypes (p < 0.05), with correspondingly low production of anti-leishmanial IL-4 and IL-10 cytokines. Significantly increased (p < 0.05) levels of nitrite, a proxy for nitric oxide, and IFN-γ expression (p < 0.05) were detected in stimulated spleen cell cultures from immunized and infected mice, as was significant production of parasite-specific IgG2a isotype antibodies. Significant reductions in the parasite load in the internal organs of the immunized and infected mice (p < 0.05) were quantified with a limiting dilution technique and quantitative PCR and correlated with the immunological findings. ChimT/MPLA showed marginally superior immunogenicity than ChimT/Sap, and although this was not statistically significant (p > 0.05), ChimT/MPLA was preferred since ChimT/Sap induced transient edema in the inoculation site. ChimT also induced high IFN-γ and low IL-10 levels from human PBMCs isolated from healthy individuals and from VL-treated patients. In conclusion, the experimental T-cell multi-epitope amastigote stage Leishmania vaccine administered with adjuvants appears to be a promising vaccine candidate to protect against VL.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.departmentMEDICINA - FACULDADE DE MEDICINApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofVaccinespt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectVisceral leishmaniasispt_BR
dc.subjectVaccinept_BR
dc.subjectT-cell epitopespt_BR
dc.subjectPolypeptide-based proteinpt_BR
dc.subjectImmune responsept_BR
dc.subjectAdjuvantspt_BR
dc.subject.otherVacinaçãopt_BR
dc.subject.otherCélulas T.pt_BR
dc.subject.otherPeptídeospt_BR
dc.subject.otherImunidadept_BR
dc.titleA Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infectionpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.mdpi.com/2076-393X/10/7/1146pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-7882-215Xpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7852-0300pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8394-4802pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1303-0490pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9663-4731pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6681-9014pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection (1).pdf705.93 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.